Telix Pharmaceuticals Ltd
TLX7.140USD
-0.290-3.90%
Handelsschluss 02/03, 16:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Telix Pharmaceuticals Ltd Unternehmen
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd Informationen
BörsenkürzelTLX
Name des UnternehmensTelix Pharmaceuticals Ltd
IPO-datumNov 15, 2017
CEOOrtiz (Raphaeel)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
Addresse55 Flemington Road
StadtMELBOURNE
BörseNASDAQ OMX - NASDAQ BASIC
LandAustralia
Postleitzahl3051
Telefon61390933855
Websitehttps://telixpharma.com/
BörsenkürzelTLX
IPO-datumNov 15, 2017
CEOOrtiz (Raphaeel)
Führungskräfte von Telix Pharmaceuticals Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Jan 18
Aktualisiert: Sun, Jan 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
Andere
99.81%
Aktionäre
Aktionäre
Anteil
Millennium Management LLC
0.06%
Portland Investment Counsel Inc.
0.04%
Fidelity Management & Research Company LLC
0.04%
Lazard Asset Management, L.L.C.
0.03%
Jane Street Capital, L.L.C.
0.02%
Andere
99.81%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
0.11%
Hedge Fund
0.06%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.02%
Andere
99.76%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
40
844.56K
0.25%
+354.04K
2025Q3
25
456.14K
0.13%
+379.51K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Millennium Management LLC
196.74K
0.06%
+196.74K
--
Sep 30, 2025
Portland Investment Counsel Inc.
128.00K
0.04%
+128.00K
--
Sep 30, 2025
Fidelity Management & Research Company LLC
118.48K
0.04%
+76.39K
+181.48%
Sep 30, 2025
Lazard Asset Management, L.L.C.
114.62K
0.03%
+114.62K
--
Sep 30, 2025
Jane Street Capital, L.L.C.
72.99K
0.02%
+37.89K
+107.94%
Sep 30, 2025
Marshall Wace LLP
48.57K
0.01%
+48.57K
--
Sep 30, 2025
Private Advisor Group LLC
42.11K
0.01%
+16.95K
+67.33%
Sep 30, 2025
IHT Wealth Management, LLC
26.21K
0.01%
+12.97K
+97.95%
Sep 30, 2025
JPMorgan Private Bank (United States)
25.36K
0.01%
+25.36K
--
Sep 30, 2025
Vanguard Personalized Indexing Management, LLC
18.38K
0.01%
-97.00
-0.53%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
